Bausch + Lomb
Bausch + Lomb Corporation is a global eye health enterprise manufacturing contact lenses, lens care solutions, ophthalmic surgical systems, and ocular pharmaceuticals. The company operates through business segments including Vision Care, producing contact lenses under Biotrue and ULTRA, Surgical, manufacturing cataract/vitreoretinal equipment, and Pharmaceuticals, producing prescription eye drops under Lumify and Vyzulta. Revenue is generated through wholesale product sales directly to eye care professionals, optical retail chains, surgical centers, and pharmacies worldwide. Core end markets encompass optometrists, ophthalmologists, surgical hospital centers, optical retailers, and eye care patients globally. Bausch + Lomb holds a market-leading global position as a premier pure-play eye health company. The corporation is incorporated in Canada, headquartered in Vaughan, Canada and Bridgewater, New Jersey, and its common shares trade on the NYSE and Toronto Stock Exchange.
3 of the funds FundTelligence covers report a position in Bausch + Lomb.
- Legal name
- Bausch + Lomb Corp
- Sector
- Health Care
- Country
- Canada
- Funds holding it
- 3
- Exposure themes
- Ageing & Longevity, Healthy Ageing & Function, Vision
Funds holding Bausch + Lomb
- T. Rowe Price Global High Yield Bond Fund — T. Rowe Price · 0.55 % (full portfolio disclosed, September 2026)
- Templeton Global High Yield — Franklin Templeton · 0.21 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)